UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Natural language processing for automated breast cancer recurrence detection and classification in computed tomography reports

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e13591-e13591

2024

Volltextzugriff (PDF)

45 Health-Related Quality of Life After Combined External Beam and Either High Dose Rate (HDR) or Low Dose Rate (LDR) Brachytherapy: Did the Rectal Dose from the LDR Brachytherapy Make a Difference?

Radiotherapy and oncology, 2023-09, Vol.186, p.S23

2023

Volltextzugriff (PDF)

Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial

International journal of radiation oncology, biology, physics, 2022-11, Vol.114 (4), p.617-626

2022

Volltextzugriff (PDF)

171: Impact of Quality Assurance and Feedback on Radiotherapy Prescribing Practices: A Randomized Controlled Trial

Radiotherapy and oncology, 2022-09, Vol.174, p.S71-S72

2022

Volltextzugriff (PDF)

Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial

International journal of radiation oncology, biology, physics, 2024-04, Vol.118 (5), p.1497-1506

2024

Volltextzugriff (PDF)

Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial

Radiotherapy and oncology, 2023-05, Vol.182, p.109576-109576, Article 109576

2023

Volltextzugriff (PDF)

Thursday, June 22, 20239:20 AM - 10:20 AMPP01 Presentation Time: 9:20 AM: Health-Related Quality of Life After Combined External Beam and Either High Dose Rate (HDR) or Low Dose Rate (LDR) Brachytherapy: Does the Rectal Dose from the LDR Brachytherapy Make a Difference?

Brachytherapy, 2023-09, Vol.22 (5), p.S16-S16

2023

Volltextzugriff (PDF)

Thursday, June 22, 20239:20 AM - 10:20 AMPP01 Presentation Time: 9:20 AM

Brachytherapy, 2023-09, Vol.22 (5), p.S16

2023

Volltextzugriff (PDF)

Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer: A Review

JAMA : the journal of the American Medical Association, 2019-08, Vol.322 (8), p.764

2019

Volltextzugriff (PDF)

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

PloS one, 2017-08, Vol.12 (8), p.e0182665-e0182665

2017

Volltextzugriff (PDF)

Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer

Otolaryngology-head and neck surgery, 1995-10, Vol.113 (4), p.408-412

1995

Volltextzugriff (PDF)

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-10, Vol.36 (28), p.2872-2878

2018

Volltextzugriff (PDF)

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non-Small Cell Lung Cancer

Clinical cancer research, 2018-01, Vol.24 (2), p.334-340

2018

Volltextzugriff (PDF)

Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade

Journal of clinical oncology, 2019-12, Vol.37 (36), p.3546-3555

2019

Volltextzugriff (PDF)

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

Annals of oncology, 2020-05, Vol.31 (5), p.599-608

2020

Volltextzugriff (PDF)

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer

Clinical cancer research, 2021-04, Vol.27 (8), p.2209-2215

2021

Volltextzugriff (PDF)

Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

Hematology/oncology clinics of North America, 2017-02, Vol.31 (1), p.101-111

2017

Volltextzugriff (PDF)

Observational Evidence for Cosmological Coupling of Black Holes and its Implications for an Astrophysical Source of Dark Energy

Astrophysical journal. Letters, 2023-02, Vol.944 (2), p.L31

2023

Volltextzugriff (PDF)

Diverse alterations associated with resistance to KRAS(G12C) inhibition

Nature (London), 2021-11, Vol.599 (7886), p.679-683

2021

Volltextzugriff (PDF)

A Preferential Growth Channel for Supermassive Black Holes in Elliptical Galaxies at z ≲ 2

The Astrophysical journal, 2023-02, Vol.943 (2), p.133

2023

Volltextzugriff (PDF)

Improving therapy for patients with epidermal growth factor receptor‐mutant lung cancer

Cancer, 2018-06, Vol.124 (11), p.2272-2275

2018

Volltextzugriff (PDF)

Identification and analysis of the bacterial endosymbiont specialized for production of the chemotherapeutic natural product ET-743

Environmental microbiology, 2015-10, Vol.17 (10), p.3964-3975

2015

Volltextzugriff (PDF)

1 – 25 von 139

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(127)
Mit Volltextzugriff
(122)

Publikationsform

Artikel
(137)
Bücher
(1)
Berichte
(1)

Sprache

Englisch
(138)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(80)
Astronomy And Astrophysics
(48)
Physical Sciences
(46)
Astronomy & Astrophysics
(39)
Life Sciences & Biomedicine
(30)
Oncology
(23)
Astrophysics
(22)
Humans
(22)
Galaxies
(21)
Physics
(21)
Dark Energy
(16)
Red Shift
(16)
Mutation
(12)
Female
(11)
Large-Scale Structure Of Universe
(11)
Lung Cancer
(10)
Lung Neoplasms - Drug Therapy
(10)
Male
(10)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(9)
Cosmology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Natural language processing for automated breast cancer recurrence detection and classification in computed tomography reports

45 Health-Related Quality of Life After Combined External Beam and Either High Dose Rate (HDR) or Low Dose Rate (LDR) Brachytherapy: Did the Rectal Dose from the LDR Brachytherapy Make a Difference?

Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial

171: Impact of Quality Assurance and Feedback on Radiotherapy Prescribing Practices: A Randomized Controlled Trial

Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial

Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial

Thursday, June 22, 20239:20 AM - 10:20 AMPP01 Presentation Time: 9:20 AM: Health-Related Quality of Life After Combined External Beam and Either High Dose Rate (HDR) or Low Dose Rate (LDR) Brachytherapy: Does the Rectal Dose from the LDR Brachytherapy Make a Difference?

Thursday, June 22, 20239:20 AM - 10:20 AMPP01 Presentation Time: 9:20 AM

31 Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-Based SABR-5 Phase II Trial

58 Should Organs at Risk (OARS) be Prioritized Over Target Volume Coverage in Stereotactic Ablative Radiotherapy (SABR) for Oligometastases? a Secondary Analysis of the Population-Based Phase II SABR-5 Trial

Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer: A Review

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non-Small Cell Lung Cancer

Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer

Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

Observational Evidence for Cosmological Coupling of Black Holes and its Implications for an Astrophysical Source of Dark Energy

Diverse alterations associated with resistance to KRAS(G12C) inhibition

A Preferential Growth Channel for Supermassive Black Holes in Elliptical Galaxies at z ≲ 2

Improving therapy for patients with epidermal growth factor receptor‐mutant lung cancer

Identification and analysis of the bacterial endosymbiont specialized for production of the chemotherapeutic natural product ET-743

Suchergebnisse filtern